TD Private Client Wealth LLC Acquires 2,501 Shares of Haleon plc (NYSE:HLN)

TD Private Client Wealth LLC increased its holdings in shares of Haleon plc (NYSE:HLN) by 9.6% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 28,463 shares of the company’s stock after purchasing an additional 2,501 shares during the quarter. TD Private Client Wealth LLC’s holdings in Haleon were worth $272,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of HLN. Thrivent Financial for Lutherans lifted its stake in shares of Haleon by 69.0% in the 3rd quarter. Thrivent Financial for Lutherans now owns 55,593 shares of the company’s stock valued at $588,000 after purchasing an additional 22,701 shares during the period. PNC Financial Services Group Inc. boosted its holdings in Haleon by 3.1% during the third quarter. PNC Financial Services Group Inc. now owns 211,326 shares of the company’s stock worth $2,236,000 after buying an additional 6,381 shares during the last quarter. King Luther Capital Management Corp acquired a new position in shares of Haleon during the 3rd quarter worth about $158,000. Charles Schwab Investment Management Inc. increased its stake in shares of Haleon by 41.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 203,583 shares of the company’s stock valued at $2,154,000 after acquiring an additional 59,719 shares during the last quarter. Finally, Cerity Partners LLC raised its position in shares of Haleon by 23.4% in the 3rd quarter. Cerity Partners LLC now owns 576,533 shares of the company’s stock valued at $6,100,000 after acquiring an additional 109,311 shares during the period. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Stock Performance

Shares of Haleon stock opened at $10.13 on Tuesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The firm has a market cap of $45.88 billion, a price-to-earnings ratio of 29.81, a price-to-earnings-growth ratio of 2.82 and a beta of 0.25. The stock’s 50-day moving average is $9.87 and its 200-day moving average is $9.88. Haleon plc has a one year low of $7.99 and a one year high of $10.80.

Haleon (NYSE:HLN) last released its earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. The firm had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. Equities analysts predict that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The firm also recently announced a — dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be given a $0.1166 dividend. The ex-dividend date of this dividend is Friday, April 25th. This represents a yield of 1.6%. This is an increase from Haleon’s previous — dividend of $0.05. Haleon’s dividend payout ratio (DPR) is 58.97%.

Analysts Set New Price Targets

Several brokerages have commented on HLN. Morgan Stanley downgraded shares of Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Haleon in a research note on Monday, March 3rd. HSBC reissued a “hold” rating on shares of Haleon in a research note on Wednesday, March 5th. Hsbc Global Res lowered Haleon from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Finally, Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Six research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.